Duloxetine in practice-based clinical settings: Assessing effects on the emotional and physical symptoms of depression in an open-label, multicenter study

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 9, Issue 4, 2007, Pages 271-279

  Wohlreich, Madelaine M ^a   Wiltse, Curtis G ^a   Desaiah, Durisala ^a   Ye, Wenyu ^a   Robinson, Rebecca L ^a   Kroenke, Kurt ^b   Kornstein, Susan G ^c   Greist, John H ^d  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d Healthcare Technology Systems Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; DULOXETINE; LEVOTHYROXINE; ZOLPIDEM;

ADULT; AGED; AGITATION; ANXIETY; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISABILITY; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSURIA; FATIGUE; FEMALE; HEADACHE; HEART RATE; HUMAN; HYPERTENSION; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OUTPATIENT; PHASE 4 CLINICAL TRIAL; QUALITY OF LIFE; RATING SCALE; SEDATION; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; SUICIDE ATTEMPT; SYMPTOMATOLOGY; SYSTOLIC BLOOD PRESSURE; VITAL SIGN; VOMITING; XEROSTOMIA;

EID: 34547697583     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/pcc.v09n0404     Document Type: Article

References (43)

1. Roy-Byrne PP, Sherbourne CD, Craske MG, et al. Moving treatment research from clinical trials to the real world. Psychiatr Serv 2003;54:327-332
2. Bymaster FP, Dreshfield-Ahmed LJ, Threlkeld PG, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001;25:871-880
3. Detke MJ, Lu Y, Goldstein DJ. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;63:308-315
4. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002;36:383-390
5. Goldstein DJ, Mallinckrodt C, Lu Y, et al. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002;63:225-231
6. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004;24:389-399
7. Wohlreich MM, Martinez JM, Mallinckrodt CH, et al. An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches. J Clin Psychopharmacol 2005;25:552-560
8. Rollman BL, Hanusa BH, Belnap BH, et al. Race, quality of depression care, and recovery from a depression in primary care setting. Gen Hosp Psychiatry 2002;24:381-390
9. Gilmer WS, Trivedi MH, Rush AJ, et al. Factors associated with chronic depressive episodes: a primary report from the STAR-D project. Acta Psychiatr Scand 2005;112:425-433
10. Kales HC, Neighbors HW, Blow FC, et al. Race, gender, and psychiatrists' diagnosis and treatment of major depression among elderly patients. Psychiatr Serv 2005;56:721-728
11. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40
12. Sherbourne C, Schoenbaum M, Wells KB, et al. Characteristics, treatment patterns, and outcomes of persistent depression despite treatment in primary care. Gen Hosp Psychiatry 2004;26:106-114
13. Corey-Lisle PK, Nash R, Stang P, et al. Response, partial response, and nonresponse in primary care treatment of depression. Arch Intern Med 2004;164:1197-1204
14. Rush AJ, Bose A. Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting. Depress Anxiety 2005;21:26-32
15. Nemeroff CB, Schatzberg AF, Goldstein DJ, et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 2002;36:106-132
16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
17. Guy W. ECDEU Assessment Manual for Psychopharmacology, revised. Rockville, Md: National Institute of Mental Health (NIMH), Psychopharmacology Research Branch; 1976:217-222, 313-331
18. Barsky AJ, Wyshak G, Klerman GL. Hypochondriasis: an evaluation of the DSM-III criteria in medical outpatients. Arch Gen Psychiatry 1986;43:493-500
19. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-item Quick Inventory of Depressive Symptomatology (QIDS), Clinician Rating (QIDS-C), and Self-Report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003;54:573-583
20. Endicott J, Nee J, Harrison W, et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993;29:321-326
21. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol 1996;11(suppl 3):89-95
22. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984;79:516-524
23. Lunceford JK, Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med 2004;23:2937-2960
24. Kornstein SG, Wohlreich MM, Mallincrodt CH, et al. Duloxetine efficacy for major depressive disorder in male vs female patients: data from 7 randomized, double-blind, placebo-controlled trials. J Clin Psychiatry 2006;67:761-770
25. Wohlreich MW, Mallinckrodt CH, Watkin JG, et al. Duloxetine for the long-term treatment of major depressive disorder in patients aged 65 and older: an open-label study. BMC Geriatrics 2004;4:11-20
26. Lewis-Fernandez R, Blanco C, Mallincrodt CH, et al. Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy in US Hispanic and majority Caucasian patients. J Clin Psychiatry 2006;67:1379-1390
27. Bailey RK, Mallincrodt CH, Wohlreich MM, et al. Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy. J Natl Med Assoc 2006;98:437-447
28. Bair MJ, Robinson RL, Eckert GJ, et al. Impact of pain on depression treatment response in primary care. Psychosom Med 2004;66:17-22
29. Cuffel BJ, Azocar F, Tomlin M, et al. Remission, residual symptoms, and nonresponse in the usual treatment of major depression in managed clinical practice. J Clin Psychiatry 2003;64:397-402
30. Swindle RW Jr, Cronkite RC, Moos RH. Risk factors for sustained nonremission of depressive symptoms: a 4-year follow-up. J Nerv Ment Dis 1998;186:462-469
31. Kroenke K, Spitzer RL, Williams JB, et al. Physical symptoms in primary care. Predictors of psychiatric disorders and functional impairment. Arch Fam Med 1994;3:774-779
32. Gerber PD, Barrett JE, Barrett JA, et al. The relationship of presenting physical complaints to depressive symptoms in primary care patients. J Gen Intern Med 1992;7:170-173
33. Kroenke K. Physical symptom disorder: a simpler diagnostic category for somatization-spectrum conditions. J Psychosom Res 2006;60:335-339
34. Bair MJ, Robinson RL, Katon W, et al. Depression and pain comorbidity: a literature review. Arch Intern Med 2003;163:2433-2445
35. Fava M, Mallinckrodt CH, Detke MJ, et al. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J Clin Psychiatry 2004;65:521-530
36. Karp JF, Scott J, Houck P, et al. Pain predicts longer time to remission during treatment of recurrent depression. J Clin Psychiatry 2005;66:591-597
37. Thomas L, Mulsant BH, Solano FX, et al. Response speed and rate of remission in primary and specialty care of elderly patients with depression. Am J Geriatr Psychiatry 2002;10:583-591
38. Robinson RL, Long SR, Chang S, et al. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims. J Manag Care Pharm 2006;12:43-54
39. Shasha M, Lyons JS, O'Mahoney MT, et al. Serotonin reuptake inhibitors and the adequacy of antidepressant treatment. Int J Psychiatry Med 1997;27:83-92
40. Vergouwen ACM, Bakker A, Katon WJ, et al. Improving adherence to antidepressants: a systematic review of interventions. J Clin Psychiatry 2003;64:1415-1420
41. Wells KB. Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research. Am J Psychiatry 1999;156:5-10
42. Zimmerman M, Chelminski I, Posternak MA. Generalizability of antidepressant efficacy trials: differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trial. Am J Psychiatry 2005;162:1370-1372
43. Keefe RS, Mohs RC, Bilder RM, et al. Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. Schizophr Bull 2003;29:45-55